the benefits of glp-1 drugs beyond obesity Unstoppable Rise Agonists: Revolutionising Diabetes and Treatment GLP-1-based therapies for diabetes, obesity

Obesity and Comorbidities in Patients With PWS The clinical picture is complex and varies considerably across the life stages: axial hypotonia, inability to suck, and hypothermia are common at birth, and often require prolonged incubation and use of nasogastric or gastric tube to provide adequate nutrition and to avoid short stature and/or decreased growth velocity [9]

Neither is published on the site right now

Current clinical guidance focuses primarily on managing gastrointestinal side effects during GLP-1RA treatment, with some nutrition considerations recommended based on previous literature in weight loss science [[7], [8], [9], [10], [11]]

Price it at your maintenance dose (typically 1.0 to 1.7mg), not the 0.25mg starter

As shown in Scheme 8